VKTXViking Therapeutics, Inc.

$28.50+12% 1Y

Is it safe?

Mixed

Forensics clean, with a caveat: a safe balance sheet, but big price swings.

1 good, 1 to watch, 1 neutral, 3 without data
SurvivalSafe zone

Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Insider conviction-$6.3M

Insiders were net sellers (-$6.3M, 90 days to Oct 8, 2026), selling is often routine.

Drawdown risk77% volderived · Oct 9, 2026

Large price swings, high volatility. Worst drawdown -89% · now 30% below its 52-week high.

Unless marked, from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitybehind 89% of the market
Max drawdownbehind 87% of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can VKTX take a bad year?

The deepest fall in VKTX's price history on file is −89%; it is 30% below its high today.

31.21

Altman Z-score · distress below 1.8 · safe above 3 · safe zone, the balance sheet is not what threatens this one

Annualised volatility
77%

Annualised volatility · three times the market's own swing

Worst drawdown on file
−89%

Worst drawdown on file · −30% today

Details›
Cash and short-term investments
$502M
Operating profit, trailing twelve months
−$560M
Annualised volatilitytwo years of daily moves
77%
Worst drawdown on file
−89%
Below its 52-week high
30%

Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.

On our screens:Most shorted stocks